In vitro release of the mTOR inhibitor rapamycin from poly(ethylene glycol)-b-poly(ε-caprolactone) micelles

被引:158
作者
Forrest, ML
Won, CY
Malick, AW
Kwon, GS
机构
[1] Univ Wisconsin, Sch Pharm, Div Pharmaceut Sci, Madison, WI 53705 USA
[2] Hoffmann La Roche Inc, Nutley, NJ 07110 USA
关键词
rapamycin; mTOR; nanocarrier; poly(ethylene glycol)-b-poly(epsilon-caprolactone); polymer micelle;
D O I
10.1016/j.jconrel.2005.10.008
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
An injectable formulation of rapamycin was prepared using amphiphilic block co-polymer micelles of poly(ethylene glycol)-b-poly(epsilon-caprolactone) (PEG-PCL). Drug-loaded PEG-PCL micelles were prepared by a co-solvent extraction technique. Resulting PEG-PCL micelles were less than 100 nm in diameter and contained rapamycin at 7% to 10% weight and > 1 mg/mL. PEG-PCL micelles released rapamycin over several days, t(50%) 31 h, with no burst release; however, physiological concentrations of serum albumin increased the release rate 3-fold. Alpha-tocopherol, vitamin E, was co-incorporated into PEG-PCL micelles and increased the efficiency of rapamycin encapsulation. The addition of alpha-tocopherol also slowed the release of rapamycin from PEG-PCL micelles in the presence of serum albumin, t(50%) 39 h. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:370 / 377
页数:8
相关论文
共 35 条
[1]   Amphiphilic block copolymers for drug delivery [J].
Adams, ML ;
Lavasanifar, A ;
Kwon, GS .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2003, 92 (07) :1343-1355
[2]   Micelles of methoxy poly(ethylene oxide)-b-poly(ε-caprolactone) as vehicles for the solubilization and controlled delivery of Cyclosporine A [J].
Aliabadi, HM ;
Mahmud, A ;
Sharifabadi, AD ;
Lavasanifar, A .
JOURNAL OF CONTROLLED RELEASE, 2005, 104 (02) :301-311
[3]  
[Anonymous], 2004, Drugs R D, V5, P363
[4]   In vitro characterization of PEGylated phospholipid micelles for improved drug solubilization:: Effects of PEG chain length and PC incorporation [J].
Ashok, B ;
Arleth, L ;
Hjelm, RP ;
Rubinstein, I ;
Önyüksel, H .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2004, 93 (10) :2476-2487
[5]   The TOR pathway: A target for cancer therapy [J].
Bjornsti, MA ;
Houghton, PJ .
NATURE REVIEWS CANCER, 2004, 4 (05) :335-348
[6]  
Crank J., 1957, The Mathematics of Diffusion
[7]   ACTIVITY OF RAPAMYCIN (AY-22,989) AGAINST TRANSPLANTED TUMORS [J].
ENG, CP ;
SEHGAL, SN ;
VEZINA, C .
JOURNAL OF ANTIBIOTICS, 1984, 37 (10) :1231-1237
[8]   Preparation, characterization, and drug release behaviors of drug nimodipine-loaded poly(ε-caprolactone)-poly(ethylene oxide)-poly(ε-caprolactone) amphiphilic triblock copolymer micelles [J].
Ge, HX ;
Hu, Y ;
Jiang, XQ ;
Cheng, DM ;
Yuan, YY ;
Bi, H ;
Yang, CZ .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2002, 91 (06) :1463-1473
[9]   Dosing of rapamycin is critical to achieve an optimal antiangiogenic effect against cancer [J].
Guba, M ;
Koehl, GE ;
Neppl, E ;
Doenecke, A ;
Steinbauer, M ;
Schlitt, HJ ;
Jauch, KW ;
Geissler, EK .
TRANSPLANT INTERNATIONAL, 2005, 18 (01) :89-94
[10]   POLYMERIC MICELLES - THEIR RELAXATION KINETICS [J].
HALPERIN, A ;
ALEXANDER, S .
MACROMOLECULES, 1989, 22 (05) :2403-2412